Cardiac toxicity of targeted therapies used in the treatment for solid tumours: A review

Cardiovascular Toxicology

Volumn 12, Issue 3, 2012, Pages 191-207

  Svoboda, Marek ^a   Poprach, Alexandr ^a   Dobes, Svatopluk ^a   Kiss, Igor ^a   Vyzula, Rostislav ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Cancer; Cardiotoxicity; Hypertension; Left ventricular dysfunction; Monoclonal antibodies; Protein kinase inhibitors; QT interval; Targeted therapy

Indexed keywords

ABELSON KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CATUMAXOMAB; CD135 ANTIGEN; CETUXIMAB; CYTOSTATIC AGENT; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ERLOTINIB; EVEROLIMUS; IMATINIB; NILOTINIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; SORAFENIB; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VEMURAFENIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTERIAL THROMBOEMBOLISM; BREAST CANCER; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMORBIDITY; DRUG CYTOTOXICITY; DRUG DEVELOPMENT; DRUG SAFETY; EARLY INTERVENTION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEAD AND NECK CANCER; HEALTH CARE PERSONNEL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT ASCITES; MEDICAL PRACTICE; MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PATHOPHYSIOLOGY; PATIENT MONITORING; PERICARDIAL EFFUSION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK FACTOR; SOLID TUMOR; STOMACH CANCER; TACHYCARDIA; TORSADE DES POINTES; VASCULITIS; VENOUS THROMBOEMBOLISM;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ARRHYTHMIAS, CARDIAC; FEMALE; HEART; HEART DISEASES; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MOLECULAR TARGETED THERAPY; MOLECULAR WEIGHT; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84864708613     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-012-9164-0     Document Type: Review

References (71)

1. Hardie, D. G. (2011). AMP-activated protein kinase: A cellular energy sensor with a key role in metabolic disorders and in cancer. Biochemical Society Transactions, 39(1), 1-13.
2. Dillman, R. O. (2011). Cancer immunotherapy. Cancer Bio-therapy Radiopharmacology, 26(1), 1-64.
3. Chen, M. H., Kerkelä, R., & Forrce, T. (2008). Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation, 117, 84-95.
4. Cheng, H., & Force, T. (2010). Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circulation Research, 106, 21-34.
5. Kuramochi, Y., Guo, X., & Sawyer, D. B. (2006). Neuregulin activates erbB2-dependent Src/FAK signaling and cytoskletal remodeling in isolated adult rat cardiac myocytes. Journal of Molecular and Cellular Cardiology, 41(2), 228-235.
6. Grazette, L. P., Boecker, W., Matsui, T., Semigran, M., Force, T. L., Hajjar, R. J., et al. (2004). Inhibition of ErbB2 causes mito-chondrial dysfunction in cardiomyocytes: Implications for her-ceptin-induced cardiomyopathy. Journal of the American College of Cardiology, 44(11), 2231-2238.
7. Ewer, M. S., Vooletich, M. T., Durand, J. B., Woods, M. L., Davis, J. R., Valero, V., et al. (2005). Reversibility of trast-uzumab related cardiotoxicity: New insights based on clinical course and response to medical treatment. Journal of Clinical Oncology, 23(31), 7820-7826.
8. Perez, E. A., & Rodeheffer, R. (2004). Clinical cardiac tolera-bility of trastuzumab. Journal of Clinical Oncology, 22(2), 322-329.
9. Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal of Clinical Oncology, 20(3), 719-726.
10. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001). Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.
11. Bird, B. R., & Swain, S. M. (2008). Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clinical Cancer Research, 14(1), 14-24.
12. Ewer, M. S., Perez, E. A., & Baselga, J. (2007). Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin) in HER2-positive early breast cancer. In Proceedings of the 10th international St. Gallen conference of primary therapy of early breast cancer, March 14-17, St. Gallen, Switzerland.
13. Arnold, J., Liu, P., Demers, C., Dorian, P., Giannetti, N., Haddad, H., et al. (2006). Canadian cardiovascular society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology, 22(1), 23-45.
14. Merck Serono. (2010). Erbitux (cetuximab) prescribing information. Available from: http://www.erbitux.com. Accessed October 15, 2010.
15. Force, T., Krause, D. S., & Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer, 7(5), 332-344.
16. Scappaticci, F. A., Skillings, J. R., Holden, S. N., Gerber, H. P., Miller, K., Kabbinavar, F., et al. (2007). Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. JNCI: Journal of the National Cancer Institute, 99(16), 1232-1239.
17. Genentech, Inc. (2011). Highlights of prescribing information-Avastin. Available from: http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf. Accessed December 20, 2011.
18. Huerta, S., & Li, H. C. (2009). Bevacizumab-associated hypertension: Etiology, incidence, and management. Anti Cancer Drugs, 20(special issue 2), S22-S24.
19. Zhu, X., Wu, S., Dahut, W. L., & Parikh, C. R. (2007). Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. American Journal of Kidney Diseases, 49, 186-193.
20. Scartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., et al. (2009). Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of Oncology, 20, 227-230.
21. Dincer, M., & Altundag, K. (2006). Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. The Annals of pharmacotherapy, 40(12), 2278-2279.
22. Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., et al. (2010). The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. International Journal of Cancer, 127(9), 2209-2221.
23. O'Day, S. J., Maio, M., Chiarion-Sileni, V., Gajewski, T. F., Pehamberger, H., Bondarenko, I. N., et al. (2010). Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Annals of Oncology, 21(8), 1712-1717.
24. Hasinoff, B. B., & Patel, D. (2010). The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicology and Applied Pharmacology, 249(2), 132-139.
25. Fernández, A., Sanguino, A., Peng, Z., Ozturk, E., Chen, J., Crespo, A., et al. (2007). An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. Journal of Clinical Investigation, 117(12), 4044-4054.
26. Atallah, E., Durand, J. B., Kantarjian, H., & Cortes, J. (2007). Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood, 110(4), 1233-1237.
27. Gambacorti, C., Tornaghi, L., Franceschino, A., Piazza, R., Corneo, G., & Pogliani, E. (2007). In reply to ''cardiotoxicity of the cancer therapeutic agent imatinib mesylate''. Nature Medicine, 13, 13-14.
28. Iliescu, C., Yusuf, S. W., & Swafford, J. (2005). Impact of angiotensin converting enzyme inhibitors and carvedilol on recovery of cardiac function in imatinib associated cardiomyop-athy. Journal of Cardiological Failure, 11(Suppl 6), S104.
29. Gnoni, A., Marech, I., Silvestris, N., Vacca, A., & Lorusso, V. (2011). Dasatinib: An anti-tumour agent via Src inhibition. Current Drug Targets, 12(4), 563-578.
30. Svoboda, M. (2011). Malignant pericardial effusion and cardiac tamponade (cardiac and pericardial symptoms). In I. N. Olver (Ed.), The MASCC textbook of cancer supportive care and survivorship (pp. 83-93). New York: Springer.
31. Novartis Pharmaceuticals Corporation. (2007). Nilotinib prescribing information. Available from: http://www.pharma.us. novartis.com/product/pi/pdf/ tasigna.pdf. Accessed October 15, 2010.
32. Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007). Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews Drug Discovery, 6, 734-745.
33. Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., et al. (2006). Activity of SU11248: A multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24, 16-24.
34. Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., et al. (2007). Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet, 370, 2011-2019.
35. Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., et al. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New England Journal of Medicine, 356(2), 115-124.
36. Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet, 368(9544), 1329-1338.
37. Orphanos, G. S., Ioannidis, G. N., & Ardavanis, A. G. (2009). Car-diotoxicity induced by tyrosine kinase inhibitors. Acta Oncologica, 48(7), 964-970.
38. Sano, M., Minamino, T., Toko, H., Miyauchi, H., Orimo, M., Qin, Y., et al. (2007). P53-induced inhibition of HIF-1 causes cardiac dysfunction during pressure overload. Nature, 446, 444-448.
39. Desai, J., Yassa, L., Marqusee, E., George, S., Frates, M. C., Chen, M. H., et al. (2006). Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Annals of Internal Medicine, 145, 660-664.
40. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., et al. (2003). The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. Journal of American Medical Association, 289(19), 2560-2572.
41. Hutson, T. E., Figlin, R. A., Kuhn, J. G., & Motzer, R. J. (2008). Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies. The Oncologist, 13(10), 1084-1096.
42. Telli, M. L., Witteles, R. M., Fischer, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Annals of Oncology, 19(9), 1613-1618.
43. Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., et al. (2008). Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 26(32), 5204-5212.
44. Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., et al. (2005). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the heart rhythm society. Circulation, 112(12), 1825-1852.
45. Wilhelm, S. M., Adnane, L., Newell, P., et al. (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics, 7(10), 3129-3139.
46. Wu, S., Chen, J. J., Kudelka, A., Lu, J., & Zhu, X. (2008). Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncology, 9, 117-123.
47. Bayer Pharmaceuticals. (2010). Nexavar (sorafenib) prescribing information. Available from: http://www.sorafenib.com. Accessed March 15, 2010.
48. Raschi, E., Vasina, V., Ursino, M. G., Boriani, G., Martoni, A., & De Ponti, F. (2010). Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. Pharmacology & Therapeutics, 125(2), 196-218.
49. Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., et al. (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. New England Journal of Medicine, 356(2), 125-134.
50. Perez, E. A., Byrne, J. A., Hammond, I. W., Rafi, R., Martin, A. M., Berger, M. S., et al. (2006). Results of an analysis of cardiac function in 2, 812 patients treated with lapatinib. Journal of Clinical Oncology, 24, 583.
51. Moy, B., & Goss, P. E. (2007). Lapatinib-associated toxicity and practical management recommendations. The Oncologist, 12(7), 756-765.
52. Noma, T., Lemaire, A., Naga Prasad, S. V., Barki-Harrington, L., Tilley, D. G., Chen, J., et al. (2007). b-arrestin-mediated b1-adrenergic receptor transactivation of the EGFR confers cardioprotection. Journal of Clinical Investigation, 117(9), 2445-2458.
53. Ribas, A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., et al. (2011). BRIM-2: An open-label, multi-centric phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. Journal of Clinical Oncology, 29, 8509.
54. Zelboraf. (2011). Prescribing information and medical guide for additional important safety information. Available from: http://www.zelboraf. com/safety-information/index.html and http://www.zel boraf.com/safety- information/index.html. Accessed July 10, 2011.
55. Votrient. (2011). Prescribing information. Research Triangle Park, NC, USA: GlaxoSmithKline. Available from: https://www.gsk source.com/gskprm/en/US/ adirect/gskprm?cmd=ProductDetail Page&product-id= 1279563278373&featureKey=601903. Accessed December 20, 2011.
56. Sloan, B., & Scheinfeld, N. S. (2008). Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Current Opinion in Investigational Drugs, 9(12), 1324-1335.
57. Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., et al. (2010). Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. Journal of Clinical Oncology, 28(6), 1061-1068.
58. Bjornsti, M. A., & Houghton, P. J. (2004). The TOR pathway: A target for cancer therapy. Nature Reviews Cancer, 4, 335-348.
59. Afinitor. (2011). Summary of product characteristics. Basel, Switzerland. Novartis Pharma AG. Available from: http://www. afinitor.com/global/docs/ Afinitor-CD-EN-10mg.pdf. Accessed July 10, 2011.
60. Torisel. (2011). Prescribing information for TORISEL. Pfizer, Inc. Available from: http://labeling.pfizer.com/showlabeling.aspx? ID=490. Accessed July 10, 2011.
61. Baur, B., Oroszlan, M., Hess, O., Carrel, T., & Mohacsi, P. (2011). Efficacy and safety of sirolimus and everolimus in heart transplant patients: A retrospective analysis. Transplantation Proceedings, 43(5), 1853-1861.
62. Gupta, R., & Maitland, M. L. (2011). Sunitinib, hypertension, and heart failure: A model for kinase inhibitor-mediated cardiotox-icity. Current Hypertension Reports, 13, 430-435.
63. Gotthardt, M., & Raddatz, K. (2006). Cardiac signaling: Cellular, molecular and clinical aspects. In D. Ganten & K. Ruckpaul (Eds.), Encyclopedic reference of genomics and proteomics in molecular medicine (pp. 208-214). New York: Springer.
64. Chintalgattu, V., Ai, D., Langley, R. R., Zhang, J., Bankson, J. A., Shih, T. L., et al. (2010). Cardiomyocyte PDGFR-b signaling is an essential component of the mouse cardiac response to load-induced stress. Journal of Clinical Investigation, 120(2), 472-484.
65. Engelhardt, S. (2007). Alternative signaling: Cardiomyocyte b1-adrenergic receptors signal through EGFRs. Journal of Clinical Investigation, 117(9), 2396-2398.
66. Cingelova, S., Jurga, L., & Mladosievicova, B. (2007). Kardio-toxicita adjuvantnej liecby karcinomu prsnika. Klinicka onkologie, 20(5), 330-334.
67. Mudd, J. O., & Kass, D. A. (2008). Tackling heart failure in the twenty-first century. Nature, 451, 919-928.
68. Samarel, A. M. (2005). Costamers, focal adhesions, and cardio-myocyte mechanotransduction. American Journal of Physiology-Heart and Circulatory Physiology, 289, H2291-H2301.
69. Kang, Y. J. (2006). Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. Toxicologic Pathology, 34, 58-66.
70. Brana, I., & Tabernero, J. (2010). Cardiotoxicity. Annals of Oncology, 21, vii173-vii179.
71. Cardinale, D., & Sandri, M. T. (2010). Role of biomarkers in chemotherapy-induced cardiotoxicity. Progress in Cardiovascular Diseases, 53(2), 121-129.